RCWM
RVNC

Royal Capital Wealth Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Royal Capital Wealth Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-6,875
Closed -$221K – 102
2023
Q1 		$221K Buy
+6,875
New +$214K 0.22% 86

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Royal Capital Wealth Management's RVNC Position: Q2 2023 in Review

Royal Capital Wealth Management sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2023, closing a stake of 6,875 shares — an estimated $221K sold.

Royal Capital Wealth Management first reported a position in RVNC in Q1 2023 and held it in 1 quarter. The position peaked at $221K in Q1 2023. 215 funds tracked by Wall St. Rank hold RVNC as of Q2 2023.

  • Royal Capital Wealth Management reported no remaining Revance Therapeutics, Inc. position as of Q2 2023 after selling out during the quarter.
  • Royal Capital Wealth Management sold 6,875 Revance Therapeutics, Inc. shares in Q2 2023, an estimated $221K.
  • Royal Capital Wealth Management first reported a position in Revance Therapeutics, Inc. in Q1 2023 and held it in 1 quarter.
  • Royal Capital Wealth Management's Revance Therapeutics, Inc. position peaked at $221K in Q1 2023.
  • 215 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2023.

Based on Royal Capital Wealth Management's 13F filing for Q2 2023, filed 11 Aug 2023.